Therapy for obsessive compulsive head banging

Details Therapy for obsessive compulsive head banging Therapy for obsessive compulsive head banging

2008-07-08

2008-07-08

Foley, Shanon A. (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S184100, C424S234100, C424S236100

Reexamination Certificate

active

10423778

ABSTRACT:
Methods for treating a head banging disorder by local administration of aClostridialtoxin. The local administration can be by intramuscular, transdermal, intradermal or subdermal administration of a low dose ofbotulinumtoxin.

REFERENCES:
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5670484 (1997-09-01), Binder
patent: 5714468 (1998-02-01), Binder
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6063768 (2000-05-01), First
patent: 6113915 (2000-09-01), Aoki et al.
patent: 6139845 (2000-10-01), Donovan
patent: 6143306 (2000-11-01), Donovan
patent: 6265379 (2001-07-01), Donovan
patent: 6299893 (2001-10-01), Schwartz et al.
patent: 6306403 (2001-10-01), Donovan
patent: 6306423 (2001-10-01), Donovan et al.
patent: 6312708 (2001-11-01), Donovan
patent: 6328977 (2001-12-01), Donovan
patent: 6358513 (2002-03-01), Voet et al.
patent: 6365164 (2002-04-01), Schmidt
patent: 6395277 (2002-05-01), Graham
patent: 6423319 (2002-07-01), Brooks et al.
patent: 6458365 (2002-10-01), Aoki et al.
patent: 6464986 (2002-10-01), Aoki et al.
patent: 6620415 (2003-09-01), Donovan
patent: 6688311 (2004-02-01), Hanin
patent: 6689816 (2004-02-01), Fogel
patent: 6955813 (2005-10-01), Brooks et al.
patent: 2001/0053370 (2001-12-01), Donovan
patent: 2003/0234727 (2003-12-01), Perlman
patent: 2004/0157926 (2004-08-01), Heresco-Levy et al.
patent: 2006/0286127 (2006-12-01), Van Schaack et al.
Jankovic, Neurology 1993, Apr. 43 (4 Supp 2).
Jankovic, Movement Disorders, vol. 9, No. 3, 1994).
Schantz et al, Microbiological Reviews, Mar. 1992, p. 80-92.
Granana et al, Seminars in Pediatric Neurology, Sep. 6, 1999, Vo. 6. No. 3, pp. 221-224.
Hashizume et al, (Psychiatry and Clinical Neurosciecnes (2002), 56, 255-256).
Granana et al (Seminars in Pediatric Neurology, Sep. 6, 1999, vol. 6. No. 3, pp. 221-224).
Hashizume et al (Psychiarty and Clinical Neurosciecnes (2002), 56, 255-256).
Hsiung et al (Movement Disorders: Official Journal of Movement Disorder Society, Nov. 1001, 17(6), 1288-93) (Abstract only).
Micheli et al (Clinical Neuropharmacology Sep.-Oct. 2002, Vo. 25, No. 5, pp. 2606-263) (Abstract only).
Denislic et al (Annals of the New York Academy of Sciences, Mar. 9, 1994, 710, p. 76-87).
Stedmans's Medical Dictionary, 24, Edition, Williams & Wilkins.
Leung et al (J Singapore Paediatr. Soc., 1990; 32(1-2):14-17).
Micheli et al (Clinical Neuropharmacology, Sep.-Oct. 2002, vol. 25, No. 5, p. 260-262). (Abstract only).
U.S. Appl. No. 10/423,380, filed Mar. 25, 2003, Alan H. Ackerman.
U.S. Appl. No. 10/423,384, filed Mar. 25, 2003, Alan H. Ackerman.
U.S. Appl. No. 10/424,050, filed Mar. 25, 2003, Alan H. Ackerman.
U.S. Appl. No. 10/424,009, filed Mar. 25, 2003, Alan H. Ackerman.
Aoki, K.R. et al., Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions;European Journal Neurology; 2001; 8 (Suppl 5):pp. 21-29.
Aoki, K.R.; Physiology and Pharmacology of Therapeutic Botulinum Neurotoxins; In: Kreyden OP, ed.Hyperhidrosis and Botulinum Toxin in Dermatology; Current Problems in Dermatology: Basel, Karger; 2002; 30: pp. 107-116.
Bigalke, Hans et al., Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture;Brain Res; 1985; 360: pp. 381-424.
Bigalke, H. et al., Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations from Rat Brain and Spinal Cord;Naunyn Schmiedebergs Arch Pharmacol; 1981; 316; pp. 244-251.
Binz, Thomas et al., The Complete Sequence of Botulinum Neurotoxin Type A and Comparison with Other Clostridial Neurotoxins;J Biochem; (Tokyo) Jun. 5, 1990; 265(16); pp. 9153-9158.
Brem, Henry et al., Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas;The Lancet;vol. 345; Apr. 22, 1995; pp. 1008-1012.
Brin, Mitchell F. et al., Botulinum Toxin Type A: Pharmacology; In: Mayer Nathaniel H, ed.Spasticity: Etiology, Evaluation, Management and the Role of Botulinum Toxin; 2002; pp. 110-124.
Chappell, Phillip et al., Fulture Therapies of Tourette Syndrome;Neurol Clin; 1997; vol. 15, No. 2, May; pp. 429-450.
Cui, M. et al., Mechanisms of the Antinociceptive Effect of Subcutanous Botox® : Inhibition of Peripheral and Central Nociceptive Processing;Naunyn Schmiedebergs Arch Pharmacol; 2002; 365 (Suppl 2) R17; Abstract.
Dabrowski, E. et al., Botulinum Toxin as a Novel Treatment for Self Mutilation in Lesch-Nyhan Syndrome;Ann Neurol; 2002; 52(3): S157; Abstract.
Duggan, Michael J. et al., A survey of botulinum neurotoxin substrate expression in cells;Mov Disord; 1995; May; 10(3) p. 376.
Fauci et al.,Harrison's Principles of Internal Medicine; 14thed.
Ferrari, David M. et al., The protein disulphide-isomerase family: unravelling a string of folds;Biochem J; 1999 (339) pp. 1-10.
Fung, Lawrence K. et al., Pharmacokinetics of Interstitial Delivery of Carmustine, 4-Hydroperoxycyclophosphamide, and Paclitaxel from a Biodegradable Polymer implant in the Monkey Brain;Cancer Research; 58, Feb. 15, 1998; pp. 672-684.
Guyton, Arthur C. et al.,Textbook of Medical Physiology 10thed; W.B. Saunders Company, pp. 686-688.
Habermann, E., I-Labeled Neurotoxin from Clostridium Botulinum A: Preparation, Binding to Synaptosomes and Ascent to the Spinal Cord;Naunyn Schmiedeberg's Arch. Pharmacol; 1974; (281); pp. 47-56.
Habermann, E., Inhibition by tetanus and botulinum A toxin of the release of {3H}noradrenaline and {3H}GABA from rat brain homogenate;Experientia; Mar. 15, 1988; 44(3) pp. 224-226.
Habermann, E. et al., Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release from Cultured Mouse Brain;J Neurochem; vol. 51, No. 2 1988; pp. 522-527.
Jankovic, Joseph; Botulinum Toxin in the Treatment of Dystonic Tics;Movment Disorders; vol. 9, No. 3, 1994; pp. 347-349.
Jankovic, Joseph; Botulinum Toxin in the Treatment of Tics Associated with Tourette's Syndrome;Neurology; Apr. 1993; 43(4 Suppl 2); A310; Abstract.
Jankovic, Joseph et al.,Therapy with Botulinum Toxin; Marcel Dekker, Inc.; pp. 71-85; also p. 5 and 150.
Krauss, Joachim K. et al., Severe Motor Tics Causing Cervical Myelopathy in Tourette's Syndrome;Movement Disorders; vol. 11, No. 5, 1996; pp. 563-565.
Kudelko, K.M. et al., Successful treatment of recalcitrant restless legs syndrome with botulinum toxin A;Movment Disorders; 2002; 17 (Suppl 5); S242 ABS p779.
Marjama-Lyons, Jill et al., Tremore-Predominant Parkinson's Disease;Drugs&Aging; Apr. 16, 2000; (4) pp. 273-278.
Naumann, Markus et al., Botulinum Toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions;European Journal of Neurology; 1999, vol. 6 (suppl 4) pp. S111-S115.
Pearce, Bruce et al., Pharmacologic Characterization of Botulinum toxin for Basic Science and Medicine;Toxicon; 1997; 35 (9); pp. 1373-1412.
Ragona, Rosario M. et al., Management of Parotid Sialocele With Botulinum Toxin;Laryngoscope; 109; Aug. 1999 (8); pp. 1344-1346.
Sanchez-Prieto, Jose et al., Botulinum toxin A blocks glutamate exocytosis from guinea-pig cerebral cortical synaptosomes;Eur J Biochem; Jun. 1987; 165 (3); pp. 675-681.
Schantz, Edward J. et al., Properties and Use of Boulinum Toxin and Other Microbial Neurotoxins in Medicine;Microbiol Review; Mar. 1992; 56 (1); pp. 80-99.
Singh, Bal Ram; Critical Aspects of Bacterial Protein Toxins;Natural Toxins II; Edited by B. R. Singh et al., Plenum Press, New Yrok, 1996; Chapter 4, pp. 63-84.
Sloop, Richard R. et al., Reconstituted botulinum toxin type A does not lose potency in humans if it refrozen or refrigerated for 2 weeks before use;Neurology; Jan. 1997; 48 (1); pp. 249-253.
Wiegand, H. et al., I-Labelled Botulinum A Neurotoxin: Pharmacokinetics in Cats after intramuscular Injection;Naunyn Schmiedebergs Arch Pharmacol; 1976; 292; pp. 161-165.
Zigmond, et al.,Fundamental Neuroscience; 1999 by Academic Press, San Diego, CA; pp. 963-964.
Ahn, et al., Plast. Reconstr. Surg., 105, 2002,

Affiliated with

Also associated with

Rating

Therapy for obsessive compulsive head banging does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapy for obsessive compulsive head banging, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapy for obsessive compulsive head banging will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3949012